Peripheral Inflammation and Cognitive Decline in Early Parkinson's Disease: The Roles of IL-6 and TNF-α

Bhargava Kanneganti

Introduction

Parkinson's disease (PD) is a progressive neurodegenerative disorder known mainly for motor symptoms such as tremors, rigidity, and bradykinesia. However, non-motor symptoms, particularly cognitive decline, can occur even in the early stages and significantly impact patients' daily lives. Understanding what drives this cognitive decline is key to improving care and prevention strategies.

Recent studies have identified inflammation as a possible contributor. Chronic inflammation can damage neurons and disrupt brain signaling, and certain inflammatory molecules in the bloodstream, especially interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), are found at higher levels in PD patients. This review summarizes current findings on these cytokines and how they may relate to cognitive decline in early-stage PD.

IL-6 and Cognitive Decline

IL-6 is one of the most studied cytokines in neurodegenerative diseases. In PD, elevated IL-6 levels have been linked to poorer cognitive scores, including tests of memory, attention, and executive function. Ma et al. (2023) found that patients with higher IL-6 levels performed worse on the Montreal Cognitive Assessment (MoCA). IL-6 may cross the blood-brain barrier or activate brain immune cells (microglia), contributing to neuronal injury and impaired cognition.

TNF-α and Cognitive Decline

TNF-α is another key inflammatory cytokine that regulates immune responses and can induce neuronal damage when chronically elevated. Studies suggest higher TNF-α levels may correlate with cognitive deficits, though findings are less consistent than for IL-6. Zhang et al. (2020) reported higher TNF-α levels in PD patients compared to healthy controls, with potential links to worse executive function. More consistent, longitudinal evidence is still needed.

Discussion

Overall, research supports a connection between peripheral inflammation and cognitive decline in PD, particularly involving IL-6 and TNF-α. However, most studies are cross-sectional and rely on small samples. The lack of standardized cognitive testing and cytokine measurement methods limits direct comparisons. Despite these challenges, the trend suggests that inflammation may contribute to neurodegeneration in PD, potentially offering a target for early intervention.

Future Directions

Future studies should aim to better understand how inflammation contributes to cognitive decline in Parkinson's disease. Long-term, or longitudinal, studies are needed to see if elevated IL-6 and TNF-α levels can actually predict future cognitive changes instead of just reflecting disease progression. Researchers should also focus on uncovering the biological mechanisms behind this link, such as how peripheral cytokines might interact with the brain's immune system or affect specific brain regions responsible for memory and executive function. Standardizing the methods used to measure cytokines and assess cognition will also make it easier to compare results

across studies. Finally, there is a growing interest in testing whether anti-inflammatory treatments, lifestyle changes, or other interventions could help slow down or prevent cognitive decline in people with PD.

Conclusion

Peripheral inflammation, especially involving IL-6 and TNF-α, may play a role in cognitive decline in early Parkinson's disease. While the relationship is still being clarified, inflammation could serve as a biomarker or even a therapeutic target in preventing neurodegeneration. More rigorous and long-term research is essential to understand this connection and its clinical significance.

References

1. Hackett, R. A., Davies, D. R., Liao, J., Swartz, J. R., & Steptoe, A. (2019). Biomarkers of inflammation and cognition in ageing: The role of IL-6 and TNF-α. Frontiers in Aging Neuroscience, 11, 128. https://doi.org/10.3389/fnagi.2019.00128
2. Lindqvist, D., Kaufman, E., Brundin, L., Hall, S., Surova, Y., & Hansson, O. (2012). The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Journal of Neuroinflammation, 9, 115. https://doi.org/10.1186/1742-2094-9-115
3. Ma, L., Li, J., Chen, L., & Zhang, H. (2023). Serum inflammatory cytokines levels and correlation analyses in Parkinson's disease. Frontiers in Cellular and Developmental Biology, 11, 1104393. https://doi.org/10.3389/fcell.2023.1104393
4. Viana da Silva, S., Barbosa, M., & Cunha, R. A. (2023). Diagnostic accuracy of interleukin-6, interleukin-10 and tumor necrosis factor alpha cytokine levels in patients with mild cognitive impairment: Systematic review and meta-analysis. PLOS ONE, 18(2), e0288726. https://doi.org/10.1371/journal.pone.0288726
5. Zhang, J., Wei, C., Zhao, X., & Zhou, Y. (2020). A systematic review and meta-analysis of inflammatory biomarkers in Parkinson's disease. Journal of Neuroinflammation, 17, 229. https://doi.org/10.1186/s12974-020-01897-7